Patent Yard Sign in
Likely abandonedArchive

Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders

US 2009/0281112 A1 · Assignee: Fabre-Kramer Pharmaceuticals, Inc. · Inventors: KRAMER; Stephen J. et al.

USPTO PDF

Overview

The published document from the USPTO: abstract, claims, description and drawings. Open it full size

Read the whole patent

Listed from its USPTO record in Patent Yard's full-term archive. Its claims, description and drawings are in the USPTO PDF and on Google Patents, and the Claude kit works from them.

Google PatentsUSPTO PDF

Why it's free to use

  • Published November 12, 2009, and no patent has issued anywhere in its US family since.
  • Nothing has been filed in its family for more than seven years, so it is very unlikely to still be pending.
  • This status is inferred from USPTO records. Confirm it on Patent Center before relying on it.
FiledMay 7, 2009
PublishedNovember 12, 2009
StatusAbandoned (inferred)
Application number12/437245
Classification (CPC)A61K45/06 +2 more
Length19 pages

Timeline

Timeline From USPTO dates

Application filedMay 7, 2009Application publishedNov 12, 2009

Sources & verification

Official USPTO records

Full published documentText and every drawing sheet as a PDF.USPTOFile historyStatus, office actions, notices, fee records and petitions.USPTO Patent CenterPatent Public Search recordSearchable full text and bibliographic data.USPTO

Cross-check elsewhere

Google PatentsFull text, worldwide family, citing patents and legal events.patents.google.comJustia PatentsFull text, claims and classification.patents.justia.comFreePatentsOnlineFull text and PDF.freepatentsonline.comEspacenetForeign family and legal status.European Patent Office

Everything on this page comes from the USPTO record linked above.